))
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser
Manage episode 380166964 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
https://x.com/Rfonsi1/status/1206004966294294528?s=20
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
https://pubmed.ncbi.nlm.nih.gov/28655925/
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
https://pubmed.ncbi.nlm.nih.gov/33129376/
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
https://pubmed.ncbi.nlm.nih.gov/36779691/
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34388020/
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:
48 episodes
Partager
